Ascend Gene & Cell Therapies is a gene and cell therapy manufacturing specialist that has recently secured a significant £106 million Series A funding round. The company aims to improve therapies by constantly refining and innovating its approach, with a focus on creating effective gene therapies to a world-class standard. Ascend supports manufacturing and process development projects from design through to clinical and commercial scales, and it prioritizes communication, transparency, and building lasting trust with its partners.

Ascend Gene & Cell Therapies

Workable provides recruiting software and a hiring platform that allows users to find, hire, onboard, and manage employees.

msh id	COM:ASCEND-GCTX
symbol	-
name	Ascend Gene & Cell Therapies
homepage url	https://workable.com
country	GB
sector	Healthcare
industry	Biotechnology and Therapeutics
market	PRIVATE
employee count	107
crunchbase url	https://www.crunchbase.com/organization/ascend-af3f
linkedin url	https://www.linkedin.com/company/ascend-gene-cell-therapies
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	10.07
growth score 28	13.19
growth score 90	47.42
growth score 365	31.46

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:ASCEND-GCTX

Workable

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-